Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChulaCov19 BNA159
- Development stage
- Unknown
- Lead developer
- Chulalongkorn University
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ChulaCov19 BNA159 is an mRNA-based vaccine developed to prevent COVID-19, the disease caused by the SARS-CoV-2 virus. The vaccine was developed by the Chulalongkorn University Vaccine Research Center (ChulaVRC) in Thailand, in collaboration with the University of Pennsylvania and BioNet-Asia. It utilizes messenger RNA (mRNA) technology to encode the spike protein of the SARS-CoV-2 virus, thereby inducing both neutralizing antibodies and T-cell immune responses. The 'BNA159' designation refers to the specific vaccine lots manufactured in Thailand by BioNet-Asia. Clinical development has evaluated the vaccine's safety, tolerability, and immunogenicity in healthy adults and elderly populations, as well as its efficacy as a booster dose following primary vaccination with other authorized COVID-19 vaccines.
- Other names
- ChulaCov19ChulaCov-19ChulaCov 19ChulaCov19 mRNA vaccineChulaCov-19 mRNA vaccineChulaCov 19 mRNA vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on ChulaCov19 BNA159.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChulaCov19 BNA159.